Business Wire

MA-NETSCOUT-SYSTEMS

22.3.2022 11:02:06 CET | Business Wire | Press release

Share
Bad Actors Innovate, Extort and Launch 9.7M DDoS Attacks in 2021 According to the Latest NETSCOUT Threat Intelligence Report

NETSCOUT SYSTEMS, INC., (NASDAQ: NTCT) today announced findings from its bi-annual Threat Intelligence Report . During the second half of 2021, cybercriminals launched approximately 4.4 million Distributed Denial of Service (DDoS) attacks, bringing the total number of DDoS attacks in 2021 to 9.75 million. These attacks represent a 3% decrease from the record number set during the height of the pandemic but continue at a pace that's 14% above pre-pandemic levels.

The report details how the second half of 2021 established high-powered botnet armies and rebalanced the scales between volumetric and direct-path (non-spoofed) attacks, creating more sophisticated operating procedures for attackers and adding new tactics, techniques, and methods to their arsenals.

“While it may be tempting to look at the decrease in overall attacks as threat actors scaling back their efforts, we saw significantly higher activity compared to pre-pandemic levels,” said Richard Hummel, threat intelligence lead, NETSCOUT. “The reality is that attackers are constantly innovating and adapting new techniques, including the use of server-class botnets, DDoS-for-Hire services, and increased used direct-path attacks that continually perpetuate the advancement of the threat landscape.”

Other key findings from the NETSCOUT 2H2021 Threat Intelligence Report include:

  • DDoS Extortion and Ransomware Operations are on the rise. Three high-profile DDoS extortion campaigns simultaneously operating is a new high. Ransomware gangs including Avaddon, REvil, BlackCat, AvosLocker, and Suncrypt were observed using DDoS to extort victims. Because of their success, ransomware groups have DDoS extortion operators masquerading as affiliates like the recent REvil DDoS Extortion campaign.
  • VOIP Services were Targets of DDoS Extortion. Worldwide DDoS extortion attack campaigns from the REvil copycat were waged against several VOIP services providers. One VOIP service provider reported $9M-$12M in revenue loss due to DDoS attacks.
  • DDoS-for-Hire services made attacks easy to launch. NETSCOUT examined 19 DDoS-for-Hire services and their capabilities that eliminate the technical requirements and cost of launching massive DDoS attacks. When combined, they offer more than 200 different attack types.
  • APAC attacks increased by 7% as other regions subsided . Amid ongoing geopolitical tensions in China, Hong Kong, and Taiwan, the Asia-Pacific region saw the most significant increase in attacks year over year compared to other regions.
  • Server-class botnet armies arrived. Cybercriminals have not only increased the number of Internet-of-Things (IoT) botnets but have also conscripted high-powered servers and high-capacity network devices, as seen with the GitMirai, Meris, and Dvinis botnets.
  • Direct-path attacks are gaining in popularity . Adversaries inundated organizations with TCP- and UDP-based floods, otherwise known as direct-path or non-spoofed attacks. Meanwhile, a decrease in some amplification attacks drove down the number of total attacks.
  • Attackers targeted select industries . Those hardest hit include software publishers (606% increase), insurance agencies and brokers (257% increase), computer manufacturers (162% increase), and colleges, universities, and professional schools (102% increase)
  • The fastest DDoS attack recorded a 107% year-over-year increase. Using DNS, DNS amplification, ICMP, TCP, ACK, TCP RST, and TCP SYN vectors, the multi-vector attack against a target in Russia recorded 453 Mpps.

NETSCOUT's Threat Intelligence Report covers the latest trends and activities in the DDoS threat landscape. It covers data captured from NETSCOUT's Active Level Threat Analysis System (ATLAS™) coupled with insights from NETSCOUT's ATLAS Security Engineering & Response Team.

The visibility and insights compiled from the global DDOS attack data, which is represented in the Threat Intelligence Report and can be seen in the Omnis Threat Horizon portal, fuel the ATLAS Intelligence Feed used across NETSCOUT's Omnis security portfolio to detect and block threat activity for enterprises and service providers worldwide.

Visit our interactive website for more information on NETSCOUT's semi-annual Threat Intelligence Report. You can also find us on Facebook , LinkedIn , and Twitter for threat updates and the latest trends and insights.

About NETSCOUT

NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) helps assure digital business services against security, availability, and performance disruptions. Our market and technology leadership stems from combining our patented smart data technology with smart analytics. We provide real-time, pervasive visibility and insights customers need to accelerate and secure their digital transformation. Omnis® Cyber Intelligence delivers the fastest and most scalable network security solution available on the market. NETSCOUT nGenius® service assurance solutions provide real-time, contextual analysis of service, network, and application performance. And Arbor® Smart DDoS Protection by NETSCOUT products help protect against attacks that threaten availability and advanced threats that infiltrate networks to steal critical business assets. To learn more about improving service, network, and application performance in physical or virtual data centers or in the cloud, and how NETSCOUT's security and performance solutions can help you move forward with confidence, visit www.netscout.com or follow @NETSCOUT on Twitter, Facebook, or LinkedIn.

©2022 NETSCOUT SYSTEMS, INC. All rights reserved. NETSCOUT, the NETSCOUT logo, Guardians of the Connected World, Adaptive Service Intelligence, Arbor, ATLAS, Cyber Threat Horizon, InfiniStream, nGenius, nGeniusONE, and Omnis are registered trademarks or trademarks of NETSCOUT SYSTEMS, INC., and/or its subsidiaries and/or affiliates in the USA and/or other countries. Third-party trademarks mentioned are the property of their respective owners.

Social Media:

https://www.facebook.com/NETSCOUTinc

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release

AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release

Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye